Three De-suup trainees, a man and two women, have died at the national referral hospital after a Leptospirosis outbreak at a ...

The report provides a detailed analysis of the current acute respiratory distress syndrome (ARDS) marketed drugs and late-stage pipeline drugs. Inside the ARDS Market | How Tech, Awareness, Rising ...

NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that the U.S.

BioAegis’ lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS).

Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- RSBT-001, AVM0703, CYP 001, AV 001, ALT-100, STSA-1002, GEn-1124, Descartes 30, Rhu-pGSN ...

Dublin, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...

Before Clements made his discoveries, respiratory distress syndrome was the leading cause of death in premature babies, ...

The reason behind acute respiratory distress syndrome development in some patients suffering with severe respiratory illness and not others is unknown, but recent research suggests a possible ...

Charles Maldarelli, Respiratory distress when a lung surfactant loses one of its two hydrophobic tails, Proceedings of the National Academy of Sciences (2024). DOI: 10.1073/pnas.2320426121 ...